This website provides information regarding antipsychotic medication prescribing practices, side effects and related information that may be useful for individuals who are aging.
Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics (PDF format)
This Agency for Healthcare Research and Quality publication (07-EHC003-EF) discusses the scientific evidence related to the safety and effectiveness of off-label use of atypical antipsychotic medications which have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder. It is an appropriate resource for professionals, providers, caregivers, family members and individuals served.
Optimizing Pharmacological Treatment of Psychotic Disorders
This document is part of the Expert Consensus series and addresses new treatments, doses and medication sequencing based on input from American experts in the treatment of psychotic disorders. It is an appropriate resource for professional staff.
Using Antipsychotic Agents in Older Patients (PDF format)
These guidelines, directed toward professional staff, are part of the Expert Consensus Series. Family members, caregivers and individuals served will find guidance concerning appropriate use of antipsychotics in individuals who are aging, addressing when antipsychotic prescriptions may be indicated and selecting specific antipsychotics in light of diagnoses such as dementia. In addition to the guidelines, expert survey results and references and expert commentary are available.
Expert Consensus Treatment Guidelines for Schizophrenia: A Guide for Patients and Families (PDF format)
This guide, directed toward professional staff, addresses treatment developed for individuals and caregivers, based on the 1999 Expert Consensus Guidelines for Schizophrenia. This guide provides answers to some of the most frequently asked questions about treatment.
Treatment of Bipolar Disorder: A Guide for Patients and Families (PDF format)
This guide to treatment for bipolar disorder was developed for professional staff to answer commonly asked questions about bipolar disorder and its treatment. The treatment information is based on input from experts in the field of bipolar disorder.
Not All Antipsychotics Created Equal: Analysis Reveals Important Differences
This article, from the National Institutes of Health (NIH) Science Update Series, is geared toward professional staff. It questions the current classification system for antipsychotic medications given the large degree of heterogeneity that exists among the different medications.
Antipsychotics May Cause Metabolic Changes in Alzheimer’s Patients
This article, directed toward professional staff, summarizes the NIH Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study results that are specific to Alzheimer’s disease. The article is published in the April 2009 NIH Research Matters eColumn.
Maximizing the Synergy between Pharmacotherapy and Psychosocial Therapies for Schizophrenia
This article, directed toward professional staff, discusses the history of interventions for schizophrenia and the current of role of psychosocial interventions in augmenting treatment with prescription medication.
Evolving Perspectives on Individual Psychotherapy for Schizophrenia (PDF format)
This article, directed toward professional staff, is a review of clinical trials that have evaluated the efficacy of individual psychotherapy for schizophrenia.
This publication of the National Institute of Mental Health (NIMH) is for caregivers and individuals affected by schizophrenia. It can be viewed on the website, downloaded or a printed copy can be ordered in English or Spanish. This information is also available in Spanish.
The National Institute of Mental Health
NIMH is conducting clinical trials to address issues which are important to those affected by mental illness. The CATIE study compares the effectiveness and side effects of new generation and older medications prescribed to treat psychoses. This resource is appropriate for individuals served, family members, caregivers, providers and professional staff.
The U.S. Food and Drug Administration, Center for Drug Evaluation and Research
The FDA Center for Drug Evaluation and Research provides summaries of pertinent information regarding drugs they have approved. This information is provided in formats directed to individuals and healthcare providers. These materials include information about antipsychotics directed toward healthcare professionals and patient information sheets provide answers to frequently asked questions and other important information for individuals, family, and/or caregivers about specific antipsychotic medications.
For questions or comments, please contact us at TQM@dads.state.tx.us.
Updated: April 3, 2013